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Abstract
 
p73 has been identified recently as a structural and functional homologue of the tumor suppressor
p53. Here, we report that p73 stability is directly regulated by the ubiquitin–proteasome pathway.
Furthermore, we show that the promyelocytic leukemia (PML) protein modulates p73 half-life
by inhibiting its degradation in a PML–nuclear body (NB)–dependent manner. p38 mitogen-
activated protein kinase–mediated phosphorylation of p73 is required for p73 recruitment into
the PML-NB and subsequent PML-dependent p73 stabilization. We find that p300-mediated
acetylation of p73 protects it against ubiquitinylation and that PML regulates p73 stability by
positively modulating its acetylation levels. As a result, PML potentiates p73 transcriptional and
proapoptotic activities that are markedly impaired in 
 
Pml
 
   
 
 primary cells. Our findings dem-
onstrate that PML plays a crucial role in modulating p73 function, thus providing further
insights on the molecular network for tumor suppression.
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Introduction
 
p73 is a structural and functional homologue of p53 (1, 2),
able to transactivate the promoters of several p53-responsive
genes involved in apoptosis and cell cycle regulation (3–7).
Consequently, p73 can regulate cell death and growth arrest
as well as differentiation (3–7).
p73 displays a modular structure similar to p53, with ex-
tensive homology to p53, particularly in the central DNA
binding domain. However, unlike p53, p73 exists as mul-
tiple isoforms arising from both the usage of a cryptic pro-
moter in intron 3 (
 
 
 
Np73 isoforms) and differential splicing
of the COOH-terminal exons (
 
 
 
,
 
 
 
,
 
 
 
,
 
 
 
,
 
 
 
,
 
 
 
, and 
 
 
 
 iso-
forms), of which the two major forms are p73
 
 
 
 and p73
 
 
 
(5, 8).
p53 stability is regulated by ubiquitinylation, a multi-step
process in which substrate proteins are covalently modified
by the formation of polyubiquitin chains, and hence tar-
geted for proteasomal degradation. p53 ubiquitinylation
is predominantly regulated by the oncoprotein MDM2,
which functions as a ubiquitin E3 ligase (9, 10). Cellular
oncoproteins, such as c-myc, E1A, Ras, and E2F1, lead to
p53 accumulation through the induction of the alternative
reading frame, which, in turn, inhibits the ubiquitin ligase
activity of MDM2 (10). Cellular stress leads to stabilization
and accumulation of p53, mainly via posttranslation modi-
fication of the p53 protein (11). In contrast, the molecular
mechanisms regulating the steady-state levels of p73 as well
as its stability upon DNA damage remain poorly under-
stood. Unlike p53, binding of p73 to MDM2 does not target
p73 for ubiquitin-mediated proteolysis through the ubiquitin
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 APL, acute promyelocytic leukemia; CHX,
cycloheximide; DAPI, 4
 
 
 
,6-diamidino-2-phenylindole; HAT, histone
acetyltransferase; HA-Ub, HA-tagged ubiquitin; MAPK, mitogen-activated
protein kinase; MEF, mouse embryonic fibroblast; NB, nuclear body;
PML, promyelocytic leukemia; RAR
 
 
 
, retinoic acid receptor. 
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ligase function of MDM2 (12). In response to cisplatin
treatment, p73 is stabilized by c-Abl (13) as well as by the
mismatch repair protein PMS2 (14). Recent evidence
suggests that the p38 mitogen-activated protein kinase
(MAPK) pathway is required for c-Abl to promote p73 sta-
bilization through phosphorylation by p38 (15). In addition
to cisplatin, other DNA-damaging agents (16–19), TCR
stimulation (20), and oncogenic stimuli (21) have been re-
ported to induce and activate p73.
In contrast with p53, no functionally significant muta-
tions of p73 have been reported so far in cancer cells, and
p73 knockout mice did not show an increased susceptibil-
ity to spontaneous tumorigenesis (22). Nevertheless, p73 si-
lencing by hypermethylation has been reported to contrib-
ute to the pathogenesis and progression of both B- and
T-lymphoblastic leukemias (23). Interestingly, p73 has been
shown recently to play a role in determining cellular sensi-
tivity to chemotherapeutic agents (19, 24). In addition,
some p53 mutants and polymorphisms can inactivate p73
proapoptotic function, thus possibly contributing to tumor
development and drug resistance (19).
The promyelocytic leukemia (PML) tumor suppressor
gene, 
 
Pml
 
, is implicated in the pathogenesis of acute pro-
myelocytic leukemia (APL), where, as a result of a recipro-
cal chromosomal translocation, it fuses with the retinoic
acid receptor 
 
 
 
 (RAR
 
 
 
) gene, 
 
RAR
 
 
 
 (25, 26). The result-
ing PML–
 
RAR
 
 
 
 fusion gene encodes a chimeric oncopro-
tein known to act as a dominant negative PML and RAR
 
 
 
mutant (27). PML is a RING finger nuclear matrix-associ-
ated protein that typically concentrates within discrete
speckled multiprotein subnuclear domains, termed the
PML–nuclear bodies (NBs; reference 28). PML is essential
for the proper formation and stability of the PML-NB, as
its inactivation leads to the disruption of the PML-NB and
the aberrant localization of PML-NB components (28, 29).
In APL blasts, PML-RAR
 
 
 
 causes the delocalization of
PML into aberrant microspeckled nuclear structures and
the subsequent disruption of the PML-NBs (30). PML ex-
erts crucial tumor-suppressive functions such as induction
of cell cycle arrest, cellular senescence, and apoptosis (31).
We and others have recently shown that upon DNA dam-
age and oncogenic transformation, PML acts as a transcrip-
tional coactivator of p53 by favoring p53 acetylation by
CBP/p300 (32–34). Here, we report that p73 turnover is
directly regulated through a ubiquitin-dependent pathway
and that PML is a key regulator of p73 function through its
ability to inhibit this process.
 
Materials and Methods
 
Plasmids, Cell Culture, and Transfection Conditions. 
 
We have
used human HA-tagged p73 isoforms and p53 in pCDNA3 (5),
Flag-tagged PML (PML isoform IV), PML 
 
 
 
RING, PML
RBCC, and PML 
 
 
 
XcmI in pCMV-Tag 2B (32) expression
vectors. The PML 
 
 
 
XcmI mutant was generated by introduc-
ing a frameshift at amino acid 496. The following cell lines
were used: Chinese hamster–derived lung ts20 (provided by R.
Schneider, New York University School of Medicine, New
York, NY); CHO ts41 (provided by M. Brandeis, The Hebrew
University of Jerusalem, Jerusalem, Israel); monkey kidney Cos-1;
human lung carcinoma H1299; colon carcinoma HCT-116(3);
osteosarcoma Saos-2 cell lines inducible for the expression of
p73
 
 
 
, p73
 
 
 
, and p73
 
 
 
 (provided by K.H. Vousden, Beatson In-
stitute for Cancer Research, Glasgow, Scotland, UK; reference
35); 
 
Pml
 
   
 
, and wild-type mouse embryo fibroblasts (MEFs).
MEFs were transfected by using Lipofectamine 2000 reagent (In-
vitrogen) following the manufacturer’s instructions.
 
Immunoblot Analysis and Coimmunoprecipitation Assays. 
 
For
immunoblot analysis, the following antibodies were used: anti-p73
(clone 5B429; Imgenex), a rabbit polyclonal anti-p73 directed
against the carboxy terminus of simian p73 recognizing both the 
 
 
 
and 
 
 
 
 isoforms, a rabbit polyclonal anti-p73
 
 
 
 (35), two rabbit anti-
PML polyclonal antibodies (a gift from P. Freemont [Imperial Col-
lege of Science, Technology and Medicine, London, England,
UK] and K.S. Chang [The University of Texas, Houston, TX]),
anti-HA (Covance), anti-GFP (CLONTECH Laboratories, Inc.),
anti-Flag (M2; Sigma-Aldrich), anti-p27 (BD Biosciences), anti–
Cul-2 (Zymed Laboratories), anti–acetyl-lysine (Cell Signaling),
anti-PML (PG-M3), anti-Lamin A/C, anti-Bax, anti-p21, anti-
p300, anti-p38, and anti-RAR
 
 
 
 (Santa Cruz Biotechnology, Inc.).
For coimmunoprecipitation experiments, cell extracts were pre-
pared as described previously (32). After the lysates had been pre-
cleared, proteins were immunoprecipitated for 2 h at 4
 
 
 
C with 1
 
 
 
g per sample of antibody and preadsorbed on protein G–Sepha-
rose beads (Amersham Biosciences).
 
Half-Life Determination. 
 
H1299 cells were transfected with
either the empty vector or Flag-PML for 24 h, split, and seeded
in 100-mm dishes. Both H1299 and MEFs were exposed to 20
 
 
 
g/ml cycloheximide (CHX). Cells were harvested at different
time points after CHX treatment, and cell extracts were immu-
noblotted with anti-HA and anti-p73 antibodies, respectively.
 
Semiquantitative RT-PCR. 
 
Total RNA was isolated using
TRIzol reagent (Invitrogen). RNA was converted to cDNA by
reverse transcription and a 376-bp DNA fragment was amplified
by PCR using the following primers: TAp73 F1, 5
 
 
 
-GTGGG-
GAAGATGGCCCAGTC-3
 
 
 
 (
 
 
 
); and p73 R1, 5
 
 
 
-CGGGG-
TAGTCGGTGTTGGAG-3
 
 
 
 (
 
 
 
). Expression of 
 
 
 
-actin was used
as an internal standard for RNA integrity and loading. 
 
 
 
-actin
amplification (660 bp) has been performed using commercial
primers (human no. 302010 and mouse no. 302110; Stratagene)
according to the manufacturer’s instructions.
 
In Vivo p73 Degradation Assay. 
 
Cells were transfected at
34
 
 
 
C. 24 h after transfection, cells were split, seeded in 100-mm
dishes, and cultured at either 34 or 40
 
 
 
C for 36 (ts20) or 48 h
(ts41). In some experiments, cells were treated with the p38
MAPK-specific inhibitor SB 202190 (30 
 
 
 
M; Calbiochem) for
20 h.
 
In Vivo Ubiquitinylation Assay. 
 
H1299 cells were transiently
transfected with cDNAs encoding human GFP-p73
 
 
 
 or p27
and HA-tagged ubiquitin (HA-Ub) with or without PML or
p300bromo–histone acetyltransferase (HAT) expression vectors
for 24 h. In some experiments, proteasome inhibitors MG132
and lactacystin (20 
 
 
 
M; Calbiochem) or their solvent DMSO
(0.2%) were added for the last 6 h of transfection. GFP-p73– and
p27-ubiquitin conjugates were immunoprecipitated and analyzed
by SDS-PAGE.
 
siRNA studies. 
 
The sequence of small interfering (si)RNA
was selected for the following target sequence of PML cDNA:
5
 
 
 
-AACGACAGCCCAGAAGAGGAA-3
 
 
 
. Control Lamin A/C
siRNA oligonucleotides were purchased from Dharmacon. Cos-1
cells were transfected as described previously (36). 
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Immunofluorescence Microscopy. 
 
MEFs were transiently trans-
fected with an expression vector for human GFP-p73
 
 
 
 in the ab-
sence or in the presence of full-length PML or PML-RAR
 
 
 
 for
24 h. Cells were washed and fixed in 4% paraformaldehyde solu-
tion for 10 min at room temperature and permeabilized with
0.1% Triton X-100. For p73 and PML staining, cells were incu-
bated with anti-p73 (clone 5B429; Imgenex) and a rabbit poly-
clonal anti-PML antibody in PBS and 10% goat serum.
 
Phosphorylation Assay. 
 
Cells were washed twice with
DMEM without sodium phosphate and sodium pyruvate and in-
cubated at 37
 
 
 
C in the same medium supplemented with 10% fe-
tal bovine dialysed serum. After 1.5 h, medium was replaced with
the same incubation medium containing 111 MBq/ml (0.3 
 
 
 
Ci/
ml) of [
 
32
 
P]orthophosphate, and cells were incubated at 37
 
 
 
C for
3 h. After washing cells with PBS, 1 mg of cell lysate was used for
immunoprecipitation with anti-HA antibody. p73 phosphoryla-
tion was visualized by autoradiography.
 
p38 MAPK Assay. 
 
In vitro p38 MAPK assay was performed
at 30
 
 
 
C for 30 min in the presence of MAPK buffer (20 mM
Hepes, pH 7.4, 20 mM MgCl
 
2
 
, 2 mM DTT, and 0.5 mM
Na
 
3
 
VO
 
4
 
 and NaF) with 200 
 
 
 
M of cold ATP, 5 
 
 
 
Ci [
 
32
 
P]ATP,
recombinant active p38 MAPK (Upstate Biotechnology), and ei-
ther 2 
 
 
 
g of ATF-2 (Santa Cruz Biotechnology, Inc.) or 6 
 
 
 
g of
purified NH
 
2
 
-terminally His-tagged full-length p73
 
 
 
.
 
Luciferase Reporter Assay. 
 
For luciferase assays, cells were
seeded in duplicate into 12-well plates and cotransfected with a
luciferase reporter plasmid driven by the 
 
bax
 
 (
 
bax
 
-Luc) or the
 
p21waf1
 
 (
 
p21
 
-Luc) promoters and a pRL-TK encoding 
 
Renilla
 
luciferase cDNA, together with a combination of different
plasmids. Luciferase activity was assayed 24 (H1299 and Saos-2)
or 48 h (MEFs) after transfection by a dual luciferase reporter
assay system (Promega) and normalized against 
 
Renilla
 
 luciferase
activity.
 
Determination of Apoptosis. 
 
Hypodiploid events were evalu-
ated by FACS
 
®
 
 analysis using a propidium iodide staining.
 
Retroviral Infection. 
 
Retroviruses were generated by transient
transfection of Phoenix cells with pBabe or pBabe-p73
 
 
 
 retrovi-
ral vectors, using the calcium phosphate method. Filtered super-
natants were harvested every 12 h, and used to infect MEFs in
the presence of 4 
 
 
 
g/ml of polybrene. 48 h after infection, cells
were selected in 2.5 
 
 
 
g/ml puromycin for 3 d.
 
Online Supplemental Material.
 
In Fig. S1, the effect of protea-
some inhibitor treatment and inactivation of the NEDD8-acti-
vating E1 enzyme on p73 ubiquitinylation and degradation was
analyzed. Fig. S2 shows that PML specifically stabilizes TA and
DNp73 without generically affecting protein ubiquitinylation. In
Fig. S3, we show that stabilization of p73 by PML is isoform spe-
cific because PML III is not able to inhibit p73 ubiquitinylation.
In Fig. S4, the effect of histone deacetylase inhibitor treatment
and p300-mediated acetylation of p73 on its protein expression
levels is shown. Figs. S5 and S6 show that PML potentiates p73
transcriptional and proapoptotic functions, respectively. Online
supplemental material is available at http://www.jem.org/cgi/
content/full/jem.20031943/DC1.
Figure 1. p73 is degraded
through the ubiquitin–protea-
some pathway. (A) ts20 and ts41
cells were transfected with HA-
p73  and either left at 34 C
(lanes 1 and 3) or shifted to 40 C
(lanes 2 and 4). Cell lysates were
analyzed by immunoblot (IB)
with anti-HA and anti– -actin
(top) antibodies. Expression of
mRNA for p73 and  -actin was
assessed by semi-quantitative RT-
PCR analysis (bottom). (B) HCT-
116(3) cells were either left un-
treated (lane 1) or incubated
with 10  M or lactacystin (lane
2) for 12 h. Cellular extracts
were analyzed with anti-p73 an-
tibody (clone 5B429). (C) Cos-1
cells were either transfected with
the empty vector (lane 1) or with
HA-Ub (lane 2) and treated
with MG132 for 6 h. Cell lysates
were immunoprecipitated with a
rabbit  polyclonal anti-p73 anti-
body followed by IB with anti-HA
antibody. (D) ts20 cells grown at
34 C were transiently transfected
with HA-p73  alone or in com-
bination with a constitutively
active form of MKK6. 8 h after
transfection, some cultures were
shifted to 40 C. (E) Phosphory-
lation of p73 in H1299 cells
transfected with HA-p73  alone
(lane 1) or in combination with HA-MKK6 (lane 2). Cells were cultured in [32P]orthophosphate-containing medium for 3 h, and phosphorylation was
assessed by autoradiography. (F) In vitro phosphorylation of human purified His-p73  by p38 MAPK. 6  g His-p73  was incubated with 1.2 U of
recombinant purified p38 MAPK. ATF-2 was included as a control.Regulation of p73 Degradation by PML 1548
Results
p73 Degradation Occurs through Ubiquitinylation and Is Neg-
atively Regulated by the p38 MAPK Pathway.  p73 protein
levels have been shown to increase upon proteasome inhibi-
tor treatment (12, 36, 38). However, whether p73 turnover is
directly regulated by ubiquitin-mediated proteolysis remains
to be proven. The mutant ts20 cell line has a thermolabile
ubiquitin-activating E1 enzyme that is inactivated at the non-
permissive temperature of 40 C, which leads to disruption of
the ubiquitinylation process. Complete degradation of p73 
occurred at 34 C (Fig. 1 A, lane 1), whereas incubation of
ts20 cells at 40 C resulted in marked accumulation of p73
protein (Fig. 1 A, lane 2), thus indicating that an intact ubiq-
uitin system is required for p73 degradation. On the contrary,
p73 mRNA levels were considerably unaltered upon temper-
ature switch (Fig. 1 A, bottom left). Proteasome inhibi-
tor treatment of ts20 cells resulted in p73 accumulation in a
polyubiquitinylated state (Fig. S1 A, available at http://
www.jem.org/cgi/content/full/jem.20031943/DC1) and in
the appearance of higher molecular weight immunoreactive
bands of p73 that contained ubiquitin (Fig. S1 B).
Next, we used a different temperature-sensitive cell line,
ts41, expressing a thermolabile NEDD8-activating E1 en-
zyme mutant (39, 40). NEDD8 is an ubiquitin-like protein
whose covalent attachment to cullins, its only known sub-
strates, appears to increase the activity of cullin-containing
ubiquitin E3 ligase complexes (39). As shown in Fig. 1 A
(top right), p73 degradation was abrogated at 40 C (lane 2),
thus suggesting that ubiquitinylation of p73 requires an in-
Figure 2. PML protects p73 from ubiqui-
tinylation and proteasome-mediated degra-
dation. (A and B) PML increases the half-life
of both exogenous and endogenous p73.
p73 half-life was measured upon CHX (20
 g/ml) addition in H1299 cells transfected
with either HA-p73  alone or with PML
(A) and in wild type and Pml    MEFs (B).
Cells lysates were examined by IB using
anti-HA (A) or anti-p73 (B, clone 5B429)
antibody. (C) H1299 cells were cotrans-
fected with the indicated plasmids for 24 h.
Some cultures were incubated with MG132
(lanes 5 and 6). p73-Ub immunocomplexes
were analyzed by IB analysis with anti-HA
(top) and anti-GFP (bottom) antibodies.
(D) Cos-1 cells were either transfected with
the empty vector (lane 1) or with Flag-PML
(lane 2) for 24 h. Cell lysates were analyzed
with rabbit polyclonal anti-p73, anti-Flag,
and anti– -actin antibody. Semi-quantitative
RT-PCR analysis on p73 and  -actin
mRNAs in Cos-1 cells was treated as afore-
mentioned (bottom). (E) Cell lysates from
wild type and Pml    MEFs were examined
by IB using anti-p73 (clone 5B429) anti-
body. (F) Cos-1 cells were either left un-
treated (lane 1) or transfected with 200 pmol
PML (lane 2) and Lamin A/C (lane 3)
siRNA. After 48 h, cell lysates were pre-
pared and analyzed for p73, PML, Lamin
A/C, and  -actin expression by IB.Bernassola et al. 1549
tact NEDD8 pathway and presumably a cullin-dependent
ubiquitin protein ligase. Under these experimental condi-
tions, stabilization of p73 mRNA did not occur at 40 C
because p73 expression levels were substantially unaffected.
Upon temperature switch to 40 C, we found both p27
(a target of the SKP1-cullin1–F box-Roc1 E3 ubiquitin li-
gase complex) accumulation and disappearance of a slower
migrating NEDD8-modified form of cul-2, hence proving
that neddylation is effectively inhibited under these experi-
mental conditions (Fig. S1 C).
To assess whether this mechanism is of physiological rel-
evance, we studied the effect of proteasome inhibitors on
endogenous p73 protein levels. Indeed, proteasome inhibi-
tor treatment led to the accumulation of both p73  and
p73  (Fig. 1 B, lane 2, and Fig. S1 D, lanes 2 and 3). Im-
portantly, endogenous p73 was polyubiquitinylated in vivo
(Fig. 1 C, lane 2). Therefore, we conclude that the regula-
tion p73 degradation involves the ubiquitin-dependent
proteasome pathway.
p38 MAPK pathway plays a role in p73 stabilization and
activation (18). In agreement with these findings, we found
that the overexpression of a constitutively active form of
MKK6, the immediate upstream regulator of p38 MAPK,
led to reduced degradation of p73 (Fig. 1 D) and increased
p73 total phosphorylation levels (Fig. 1 E). In vitro kinase
assays showed that p73 is directly phosphorylated by p38
MAPK (Fig. 1 F). Thus, p38 MAPK signaling contributes
to both p73 phosphorylation and stabilization.
PML Protects p73 from Proteasome-mediated Degradation.
PML isoform IV regulates p53 induction and transcrip-
tional activation (32–34, 41) and protects p53 from
MDM2-mediated degradation (42, 43). Therefore, we set
out to test whether PML isoform IV might regulate p73
stability. PML overexpression indeed led to a dose-depen-
dent p73 accumulation (Fig. S2, A and B, available at http:
//www.jem.org/cgi/content/full/jem.20031943/DC1).
To test whether PML regulates p73 stability, we followed
the half-life of ectopically expressed p73 and found that it
was greatly increased by PML overexpression (Fig. 2 A),
thus demonstrating that PML stabilizes p73 in vivo. Im-
portantly, and in agreement with these results, we ob-
served that the half-life of endogenous p73  was pro-
longed in cells overexpressing PML (not depicted) and
resulted markedly shortened in Pml    compared with
wild-type MEFs (Fig. 2 B).
Next, we investigated whether PML might interfere
with the proteasome-dependent degradation of p73 and
observed that it was dose-dependently reduced by increas-
ing amounts of exogenous PML in ts20 cells (Fig. S2 C).
Similar results were obtained by using the ts41 cell line
(unpublished data).
The ubiquitinylation levels of p73 were significantly re-
duced in PML-overexpressing cells (Fig. 2 C). PML also
prevented p73 ubiquitinylation in MG132-treated cells
(Fig. 2 C, lane 6), indicating that PML acts upstream of the
proteasome degradation process. Importantly, PML did not
Figure 3. p73 and PML phys-
ically interact in vivo. (A) H1299
cells were transiently transfected
with expression vectors encod-
ing HA-p73  along with Flag-
PML. p73–PML complexes were
analyzed by IP using a monoclonal
anti-PML (PG-M3) followed by
IB with anti-HA and anti-Flag
antibodies. Unspecific bands were
recognized by the anti-Flag anti-
body in extracts from cells that
did not overexpress PML (lanes
5 and 6). (B) Saos-2 cells inducible
for p73  expression were trans-
fected with Flag-PML. 4 h after
transfection, cells were either left
untreated or stimulated with 2  g/
ml doxycycline (Dox) for 24 h.
Cell lysates were immunoprecip-
itated with anti-Flag antibody, and
the immunoprecipitate was ana-
lyzed by IB using anti-HA anti-
body. (C) Schematic presentation
of the structure of PML and its
deletion mutants. (D) p73 inter-
acts with the carboxy-terminal
domain of PML in vivo (amino
acids 436–633). Transformed 3T3
Pml    MEFs were cotransfected
with GFP-p73  and full-length
Flag-PML (lane 7), Flag-PML  RING (lane 8), Flag-PML RBCC (lane 9), or Flag-PML  XcmI. Cell lysates were immunoprecipitated with anti-Flag
antibody and the immunoprecipitate analyzed by IB using anti-HA antibody. Inputs for both p73 and PML expression are shown. The  RING mutant
comigrated with unspecific bands recognized by the anti-Flag antibody in the extracts (lanes 4 and 8).Regulation of p73 Degradation by PML 1550
exert a global inhibitory effect on the ubiquitin-dependent
degradation machinery because, for instance, it did not af-
fect p27 ubiquitinylation levels (Fig. S2 D).
Next, we examined the effect of PML on the induction
of endogenous p73 protein. Furthermore, PML overex-
pression led to a significant accumulation of endogenous
p73  and p73  isoforms (Fig. 2 D, top). PML-mediated
accumulation of p73 was not caused by any increase in p73
gene transcription or mRNA stabilization because p73 ex-
pression levels were unaffected (Fig. 2 D, bottom). p73 
protein levels were significantly reduced in Pml    versus
wild-type MEFs (Fig. 2, B and E). We down-regulated
PML expression by using siRNA oligonucleotides and
found that reduction of steady-state levels of PML resulted
in a marked decrease of both p73  and p73  protein levels
(Fig. 2 F, lanes 1 and 2). In contrast, the control Lamin
A/C siRNA did not affect either PML or p73 protein lev-
els (Fig. 2 F, lane 3). Together, these results demonstrate
that PML protects p73 against ubiquitinylation and its sub-
sequent proteasome-dependent degradation.
Figure 4. p73 and PML colo-
calization within the PML-NBs
is required for p73 stabilization
(A) Representative image of
Cos-1 cells costained with anti-
p73 (green, clone 5B429) and
anti-PML (red) antibodies and
analyzed by confocal microscopy
(left). Nuclei were visualized by
4 ,6-diamidino-2-phenylindole
(DAPI) staining. The arrows in-
dicate p73-containing speckles.
(right) A quantitative analysis of
the green and red fluorescence
intensity at distinct nuclear
speckles as indicated by the yellow
arrow. (B–D) GFP-p73  was
overexpressed into wild type (B)
and  Pml    (C) MEFs. Full-
length PML was cotransfected
with GFP-p73  into Pml   
MEFs (D). Nuclei were visualized
by DAPI staining. The arrows in-
dicate p73-containing PML-NBs.
(E) Pml    MEFs were transiently
transfected with HA-p73  alone
(lane 1) or in combination with
full-length Flag-PML (lane 2),
Flag-PML  RING (lane 3), or
PML-RAR  (lane 4). Cell ex-
tracts were subjected to IB with
anti-HA, anti-Flag, anti-RAR ,
and anti– -actin antibodies.
(bottom) Normalization of trans-
fection efficiency by quantitation
of GFP expression.Bernassola et al. 1551
PML Inhibits p73 Degradation in a PML-NB–dependent
Manner.  Because PML interacts with p53 through the
DNA binding domain (32), which is highly homologous to
that of p73 (1), next we examined whether PML and p73
also physically interact in vivo. Complexes immunoprecip-
itated with anti-PML antibody were found to contain p73
(Fig. 3 A). Similarly, doxycycline-induced p73  coimmu-
noprecipitated with PML (Fig. 3 B). To identify the PML
domain responsible for the interaction with p73, we ex-
pressed HA-p73  along with the PML  RING (32), PML
RBCC (32), and PML  Xcm1 deletion mutants (Fig. 3 C)
in Pml    MEFs to avoid heterodimerization of the various
mutants with the endogenous PML isoforms. As shown in
Fig. 3 D, the two PML mutants lacking the carboxy-termi-
nal region lost the ability to interact with p73, whereas the
absence of the PML amino-terminal domain did not influ-
ence its ability to associate with p73.
Because PML interacts with p73, next we investigated
whether PML could affect p73 sub-cellular localization.
Endogenous p73 showed a diffuse as well as a nuclear
punctuate pattern partially colocalizing with PML (Fig. 4
A). Similar results were obtained in HCT116(3) cells (un-
published data). Ectopically expressed GFP-p73  partly ac-
cumulated in speckles in wild-type MEFs (in  70% of
cells), which colocalized with PML ( 40% of PML-NBs
per cell were found to contain p73) (Fig. 4 B and see Fig. 5
D). In sharp contrast, GFP-p73  did not accumulate in
speckles, and its staining pattern remained entirely diffuse
in Pml    MEFs (Fig. 4 C).
Add-back of PML into Pml    MEF cells resulted in res-
toration of p73 PML-NB localization (Fig. 4 D). On the
contrary, transfection of Pml    MEFs with the PML
 RING mutant, which lacks the RING domain and,
therefore, does not accumulate in the PML-NBs (32), but
retains the ability to physically interact with p73 (Fig. 3 D),
did not alter the diffuse distribution pattern of p73 (not de-
picted). Similarly, the PML-RAR  oncogenic fusion pro-
tein, which exhibits an aberrant microspeckled nuclear dis-
tribution pattern, did not colocalize with p73 in these
microspeckles (unpublished data).
To examine whether colocalization of p73 and PML
into the PML-NBs is required for p73 stabilization, we
compared the effect of the aforementioned PML mutants
on p73 accumulation. We expressed HA-p73  in Pml   
MEFs along with full-length PML, PML- RING, or
PML-RAR . Strikingly, both PML- RING and PML-
RAR  were significantly less effective (two- vs. sixfold in-
duction) than wild-type PML in stabilizing p73 (Fig. 4 E
and Fig. 3 D). Similar results were obtained by using PML
mutants that had lost the ability to interact with p73 (Fig. 3
D). Furthermore, the PML III isoform, which showed a
shorter carboxy-terminal tail and, therefore, was unable to
Figure 5. p38 MAPK is re-
quired for PML-mediated inhibi-
tion of p73 degradation. (A) ts20
cells were cotransfected with
HA-p73 , GFP-spectrin with
(lanes 2 and 4) or without (lanes
1 and 3) Flag-PML for 48 h at
34 C. Some cultures were treated
with the p38 MAPK inhibitor
SB202190 (lanes 3 and 4). (B) ts20
cells were cotransfected with
GFP-spectrin, HA-p73  alone
(lanes 1 and 2) or in combination
with PML (lanes 4 and 5) in the
absence (lane 4) or in the presence
(lane 5) of p38(A/F). Whole cell
extracts were immunoblotted
with anti-HA, anti-p38, anti–
 -actin, or anti-HSP90 antibod-
ies. (C) Transfection and IP ex-
periments were performed as
described in Fig. 3 A. 8 h after
transfection, cells were incu-
bated with SB 202190 or DMSO
for 20 h. (D) Wild-type MEFs
were transfected with GFP-p73 
and either left untreated or incu-
bated with SB 202190 for 20 h.
Cells were analyzed by confocal
microscopy. Nuclei were visual-
ized by DAPI staining. The arrows
indicate p73-containing speckles.
As a control, wild-type MEFs
were also transfected with a GFP
expression vector and stained with
anti-PML (red) antibody (right).Regulation of p73 Degradation by PML 1552
bind p53, did not affect p73 ubiquitinylation (Fig. S3,
available at http://www.jem.org/cgi/content/full/jem.
20031943/DC1). In agreement with these results, treat-
ment of Cos-1 cells with arsenic trioxide, which promotes
PML modification by SUMO-1 and its subsequent recruit-
ment to the PML-NB (44), enhanced endogenous p73
protein levels (unpublished data), further substantiating the
notion that PML localization to the PML-NB is crucial for
regulation of p73 stability. Together, these results indicate
that PML influences p73 subcellular localization and that
this is crucial for regulation of p73 stability.
Furthermore, because in APL blasts, PML activity is com-
promised due to both the dominant negative action of PML-
RAR  and the reduction of Pml gene to hemizygosity (45),
the fact that PML-RAR  is defective in stabilizing p73
strongly suggests that p73 function may be impaired in APL.
The p38 MAPK Pathway Is Required for PML-dependent
p73 Stabilization.  Because p38 MAPK plays a role in p73
stabilization (Fig. 1 E and reference 15), next we asked
whether the inhibition of p38 MAPK signaling might affect
the protective effect exerted by PML on p73 degradation.
Treatment of ts20 and H1299 cells with SB 202190, a se-
lective inhibitor of p38 MAPK (46), reduced the steady-
state levels of p73 and dramatically attenuated the ability of
PML to prevent its degradation (Fig. 5 A and not de-
picted). Overexpression of a dominant negative mutant of
p38 (47), in which the TGY dual phosphorylation site is
mutated to AGF (p38[A/F]), also led to a significant reduc-
tion of PML-induced p73 accumulation (Fig. 5 B, compare
lanes 4 and 5).
To elucidate the mechanism underlying the cross-talk
between the p38 MAPK pathway and PML, we measured
p38 MAPK activation levels in wild type and Pml    MEFs
at steady-state and upon UV irradiation, and found that
they were comparable between the two genotypes (unpub-
lished data). In addition, in vivo p38 MAPK phosphoryla-
tion assays performed by using immunoprecipitates of both
endogenous and exogenous p38 MAPK did not show in-
creased kinase activity upon PML overexpression, and total
phosphorylation levels of p73 were not altered by PML
overexpression (unpublished data).
Therefore, we sought to examine whether p38 MAPK
activation is required for the ability of p73 to interact with
PML and localize in the PML-NB. Strikingly, the inhibi-
tion of p38 MAPK strongly diminished the amount of p73
associated with PML protein ( 73% reduction; Fig. 5 C).
In addition, treatment of wild-type MEFs with SB 202190
led to a decrease in the percentage of cells showing colocal-
ization of p73 and PML into the PML-NBs (71%   3 and
56%   7 in untreated vs. SB 202190–treated MEFs, re-
Figure 6. PML-regulated acetylation of p73 by p300
protects p73 against degradation. (A) GFP-p73  and
HA-Ub were expressed in 293T cells in the absence
(lane 3) or in the presence (lane 4) of p300bromo-HAT
for 24 h. Cells were incubated with 1  M trichostatin A
(TSA) and 1 mM niacinamide for the last 12 h of trans-
fection. After IP of GFP-p73, ubiquitinylation levels of
p73 were detected with anti-HA antibody. Acetylated
and unacetylated p73 in the immunoprecipitates were
determined with anti–acetyl-lysine and anti-GFP anti-
body, respectively. (B) 293T cells were transfected
with a plasmid encoding GFP-p73  alone (lane 1) or
in combination with p300bromo-HAT (lanes 2–6), in
the absence (lane 2) or in the presence (lanes 3–6) of
decreasing doses of HA-Ub for 24 h. Treatment with
deacetylase inhibitors and IP experiments were per-
formed as described in A. (C and D) Transformed 3T3
Pml    MEFs were transiently transfected with GFP-
p73  alone (lane 1) or along with p300 in the absence
(lane 2) or in the presence of full-length Flag-PML
(lane 3), Flag-PML- RING (lane 4), or Flag-PML-
RAR  (lane 5) for 24 h. Cells were incubated with
deacetylase inhibitors for 8 h. p73 was immunoprecipi-
tated using anti-GFP antibody followed by IB with
anti–acetyl-lysine antibody (C). Whole cell extracts
were immunoblotted with anti-GFP, anti-Flag, and
anti– -actin antibodies (D).Bernassola et al. 1553
spectively) as well as a decrease of PML-NBs found to con-
tain p73 per cell (36%   6 vs. 20%   1) and resulted in a
more diffuse p73 distribution pattern (Fig. 5 D, middle).
These effects were specific to p73 as GFP did not unspecif-
ically accumulate in the PML-NBs (Fig. 5 D, right). Alto-
gether, these findings demonstrate that p38 MAPK plays a
key role in modulating the ability of PML to stabilize p73
and further support the notion that the PML-NB–depen-
dent interaction of p73 and PML is critical for PML to in-
hibit p73 degradation.
PML Promotes p300-mediated Acetylation and Stabilization
of p73. p73 is a substrate for the histone acetyltransferase
(HAT) activity of p300 (18). In addition, reports have cor-
related p53 acetylation and stability (11, 48). We found that
p300-mediated acetylation of p73 as well as treatment with
histone deacetylase inhibitors increased p73 protein levels
(Fig. S4, A and B, available at http://www.jem.org/cgi/
content/full/jem.20031943/DC1). Importantly, the effect
of p300 on p73 accumulation was dependent on the in-
trinsic HAT activity of p300 because expression levels
of p73 were also increased by simply overexpressing the
p300bromo-HAT domain (Fig. S4 C).
To provide direct evidence that p300-mediated enhanced
expression of p73 reflects increased stability of the protein,
we tested the effect of p73 acetylation on its ubiquitinylation
levels in vivo. As shown in Fig. 6 A, acetylated p73 ( 90 kD
band as indicated by the arrow) was significantly less ubiqui-
tinylated than the unacetylated protein (compare lanes 3 and
4), thus demonstrating that p300-mediated modification of
p73 inhibits its ubiquitinylation. In accordance with the pre-
vious results, we found that p73 acetylation levels were
strongly reduced by high levels of protein ubiquitinylation
(Fig. 6 B). On the contrary, p73 acetylation could be re-
stored by decreasing its ubiquitinylation levels (Fig. 6 B).
Thus, competition between acetylation and ubiquitinylation
may result in regulation of p73 protein stability.
Because CBP and p300 have both been shown to colo-
calize with PML to the PML-NBs and PML is a crucial
regulator of CBP-mediated acetylation of p53 (32, 34, 49),
we investigated whether p300-mediated acetylation of p73
is modulated by PML. Restoration of PML expression
in  Pml    cells significantly increased p73 acetylation
levels (Fig. 6 C), demonstrating that PML also promotes
the acetylation of p73 in vivo. On the contrary, both
the PML- RING PML-NB–defective mutant and PML-
RAR  were unable to affect p73 acetylation levels (Fig. 6
C). Furthermore, the overexpression of PML and p300 in
Pml    cells resulted in a cooperative stabilization of p73,
whereas the add-back of PML- RING or PML-RAR 
did not affect the ability of p300 to accumulate p73 (Fig. 6
D). Together, these findings demonstrate that acetylation
leads to p73 stabilization and PML positively modulates this
process in a PML-NB–dependent manner.
PML Regulates p73 Transcriptional and Biological Activities.
Overexpression of PML resulted in enhancement of the
transactivation potential of various p73 isoforms on both
the bax-Luc and the p21-Luc promoters (Fig. S5, A and
B, available at http://www.jem.org/cgi/content/full/
jem.20031943/DC1, and not depicted). Accordingly, Bax
and p21 protein levels were enhanced by coexpression of
p73 and PML as compared with cells expressing p73 alone
(Fig. S5 C). Pml inactivation resulted in a marked impair-
ment of p73-dependent transcription. Indeed, p73  tran-
scriptional activity was diminished up to 65% in Pml   
cells (Fig. 7 A and not depicted). In agreement with the in-
ability of the PML- RING mutant to efficiently stabilize
Figure 7. PML is required for p73 transcriptional
and proapoptotic activity. (A) A bax promoter-driven
luciferase reporter plasmid (bax-Luc) alone or in com-
bination with p73  was transfected into wild type and
Pml    MEFs, and luciferase activity was assayed 48 h
after transfection. pRL-TK vector was included to
normalize transfection efficiency, and reporter basal lu-
ciferase activity was normalized as 1. Values are mean  
SEM of two separate experiments each performed in
duplicate. (B) Wild type and Pml    MEFs were retro-
virally transduced with a pBabe-p73  construct for 48 h,
selected in puromycin-containing medium for 3 d, and
scored for apoptosis by FACS® analysis using propid-
ium iodide staining. Values are mean   SEM of two
separate experiments each performed in duplicate. (C)
A model for PML-mediated protection against p73
degradation. PML inhibits p73 ubiquitin-dependent
degradation (left). PML controls p73 stability by regu-
lating p73 acetylation levels in the PML-NB, thereby
preventing its ubiquitinylation (right).Regulation of p73 Degradation by PML 1554
p73, the transcriptional defect observed in the Pml   
MEFs could be rescued by PML, but not by PML- RING
add-back (Fig. S5 D). Furthermore, SB 202190 treatment
reduced the ability of p73 to transactivate the bax-Luc pro-
moter (up to 44% inhibition; Fig. S5 E). Remarkably, PML
coactivation of p73-dependent transcription was addition-
ally impaired upon SB 202190 treatment (up to 56% inhi-
bition; Fig. S5 E).
Next, we evaluated the ability of PML to affect p73 bio-
logical functions, such as induction of apoptosis, and found
that PML can potentiate it (Fig. S6, A and B, available
at http://www.jem.org/cgi/content/full/jem.20031943/
DC1, and not depicted). Furthermore, Pml inactivation
markedly impaired p73-induced apoptosis in MEFs retro-
virally transduced with p73  or p73  constructs (Fig. 7 B
and not depicted). Thus, PML is a critical regulator of p73
transcriptional and biological functions through its ability
to regulate p73 acetylation in a NB-dependent manner.
Discussion
Our findings lead to three major conclusions. First, deg-
radation of p53 family members is regulated through distinct
molecular mechanisms. Although MDM2 has a critical
function in the negative regulation of p53 activity in vivo
(50), it does not lead to p73 degradation (12), but rather to
its stabilization (51). We show that endogenous p73 is poly-
ubiquitinylated in vivo and degraded through the ubiq-
uitin–proteasome pathway. Cullin-dependent ubiquitinyla-
tion is positively regulated by the NEDD8 pathway (39).
We also found that an intact NEDD8 system is required for
p73 degradation, suggesting that p73 ubiquitinylation might
require the NEDD8-mediated modification and consequent
activation of a cullin-dependent ubiquitin ligase. Although
NEDD8-mediated modification of cullin-containing com-
plexes has been recently implicated in adenovirus-induced
p53 degradation (52), p53 turnover at the physiological
level is mainly controlled by MDM2. This is intriguing and
surprising in view of the high degree of structural and func-
tional homology among p53 family members and may sug-
gest that the evolutionary divergence of degradation mecha-
nisms has evolved to ensure that the possible deregulation of
this process would not concomitantly affect the entire p53
family. Further studies will be required to identify the E3
ubiquitin ligase involved in p73 ubiquitinylation and to
prove that it contains a NEDD8-modified cullin subunit.
Our preliminary results indicate that either the SKP1-
cullin1–F box-Roc1 and the VEC E3 ubiquitin ligase com-
plexes are not responsible for p73 degradation.
Second, we demonstrate that PML increases p73 acetyla-
tion, thus preventing its ubiquitinylation and subsequent
degradation (Fig. 7 C, left). Our findings identify a chain of
molecular events by which p38 MAPK activation is a pre-
requisite for p73 binding to PML and recruitment into the
PML-NB, PML-dependent p300-mediated acetylation and
stabilization of p73 and its consequent transcriptional/func-
tional activation (Fig. 7 C, right). In agreement with these
findings, it has been reported that the activation of the p38
MAPK pathway enhances p73 stability by promoting its
phosphorylation on threonine and threonine residues adja-
cent to prolines (15). Also in accordance with these results,
here we demonstrate that p73 is a direct target for p38
MAPK phosphorylation.
PML mutants that exhibit aberrant nuclear distribution
patterns and do not colocalize with p73 in the PML-NB are
defective in stabilizing p73. Similarly, a recent work has
demonstrated that PML isoform IV plays a role in regulating
the stability of the DNA damage response protein topo-
isomerase II –binding protein (TopBP1) through its recruit-
ment into the PML-NB in response to  -irradiation (36).
It is becoming apparent that the PML-NB can be re-
garded as a factory for posttranslational modifications (53).
Key regulators of p53 function, such as HAUSP, a p53-
specific deubiquitinylase (54); HIPK2, a novel p53 kinase
(55); CBP; and p300 (32, 34, 49), colocalize with PML
within the PML-NB. Therefore, as with p53, p73 recruit-
ment to the PML-NB could result in multiple posttransla-
tional modifications of the protein. Here, we show that
PML indeed modulates p73 acetylation; in contrast, it does
not affect p73 sumoylation levels (unpublished data).
Competition between ubiquitinylation and acetylation
of overlapping lysine residues constitutes a novel mecha-
nism to regulate protein stability (11, 48, 56). In particular,
p300/CBP-mediated acetylation of p53 attenuates its deg-
radation by blocking the  -amino group of the lysine resi-
dues for ubiquitinylation (11, 48). Acetylation of p73 by
p300 plays a key role in potentiating its apoptotic function
in response to DNA damage by stimulating the ability of
p73 to selectively transactivate proapoptotic target genes,
such as the p53AIP1 (18). Here, we show that acetylation
of p73 can also abrogate its ubiquitinylation and stabilize
the protein, possibly by competition for the same overlap-
ping lysine residues. Further studies will be needed to iden-
tify specific lysine residues, which are targeted for acetyla-
tion/ubiquitinylation modification.
PML positively regulates the ability of p300 to acetylate
and stabilize p73, thus indicating that PML inhibits p73
ubiquitin-dependent degradation by affecting its acetyla-
tion levels. Importantly, the inability of PML mutants ex-
hibiting an aberrant nuclear distribution pattern to potenti-
ate p300-mediated acetylation and stabilization of p73
further supports a role for the PML-NB in regulation of
p73 stability. The presence of p300 in the PML-NB sug-
gests that p73 is recruited in these structures to facilitate and
regulate its acetylation, which in turn promotes stabiliza-
tion of the protein.
A recent paper (42) demonstrated that PML neutralizes
the inhibitory effects of MDM2 and, therefore, inhibits p53
degradation by prolonging the stress-induced checkpoint
kinase 2–mediated phosphorylation of p53 (42). In addi-
tion, we have found that PML is essential for MDM2 se-
questration in the nucleolus upon DNA damage, which in
turn leads to p53 accumulation (43). It remains to be estab-
lished whether the ability of PML to modulate p53 acetyla-Bernassola et al. 1555
tion also results in its stabilization. Thus, although the
mechanisms that control p53 and p73 are distinct, our data
identify PML as an important regulator of the stability of
both proteins.
Our third major conclusion suggests a role for p73 in the
pathogenesis of APL. Although the p73 gene is rarely mu-
tated, interaction of the p73 protein with dominant negative
forms of p53 and p73 ( Np73, a mutant lacking the NH2-
terminal transactivating domain) or hypermethylation of 5 
untranslated region of the p73 mRNA (23) has been ob-
served in tumors of various histological origins. It has been
reported recently that  Np73 may provide a proliferative
advantage to cancer cells by counteracting the transactiva-
tion activities of p53 as well as TAp73 (the full-length p73
isoform) and, hence, their ability to induce apoptosis (1, 8).
Indeed, several NH2-terminally deleted variants of p73 are
overexpressed in cancer cells (4) and represent a strong ad-
verse prognostic marker in certain tumors such as neuro-
blastoma (57). Therefore, it is emerging that the balance be-
tween TAp73 and  Np73 isoforms and loss of expression,
rather than gene mutation, could contribute to tumorigene-
sis. Although when overexpressed, PML appears to stabilize
both TAp73 and  Np73 isoforms (Fig. S1, A and B), it re-
mains to be determined whether or not in vivo PML would
stabilize preferentially the TAp73 isoforms, an issue that
cannot be presently addressed in view of the lack of anti-
bodies that recognize endogenous  Np73 proteins.
Among hemopoietic malignancies, loss of p73 expression
is observed in a subset of lymphomas and leukemias (23). In
addition, analysis of samples from acute myeloid leukemia
patients has revealed increased expression of low molecular
weight p73 splicing variants ( ,  , and  ), which are weaker
transcriptional activators than the larger isoforms (58). In
APL, p73 function may be impaired for at least two rea-
sons. First, the PML dose is reduced, due to the fact that
one PML allele is involved in the chromosomal transloca-
tion, and PML-RAR  is defective in p73 stabilization.
Second, disruption of the PML-NBs by PML-RAR  can
further exacerbate this defect. Our observation that PML-
RAR  acts as a dominant negative regulator of p73 acety-
lation (Fig. 6 C) strongly supports the hypothesis that sta-
bility and activity of p73 may be compromised in APL
blasts. In this respect, PML-RAR  has been reported re-
cently to destabilize p53 by promoting its deacetylation and
its subsequent MDM2-dependent degradation (59). Also,
in complete agreement with these observations, p73 pro-
tein levels are markedly increased upon retinoic acid treat-
ment of the human APL cell line NB4 (58). As retinoic
acid treatment of NB4 cells causes the degradation of the
PML-RAR  fusion protein and the reorganization of the
PML-NB (28), this may restore the ability of PML to stabi-
lize and functionally activate p73.
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